arrow
L

Lazar Velicki

University of Novi Sad
H指数:25
被引数:3,002

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Differences in clinical presentation between heart failure patients with reduced and preserved ejection fraction - analysis of the INTELHEART database: Heart Failure Phenotypes Compared

射血分数降低和保留的心力衰竭患者临床表现的差异 - INTELHEART数据库分析:心力衰竭表型比较

2026-05-011
PRE
Economic burden of heart failure in Europe: A systematic review of costs and cost-effectiveness

欧洲心力衰竭的经济负担:一项关于成本和成本效益的系统综述

2025-11-010
OAAI
The Long-Term Outcomes of Corticosteroid Use in COVID-19 Patients with Cardiovascular Disease: A Propensity-Matched Analysis from the Multi-Center International Prospective Registry (HOPE-2)

心血管疾病患者使用糖皮质激素治疗COVID-19的长期结局:一项来自多中心国际前瞻性登记研究(HOPE-2)的倾向性匹配分析

2025-10-300
OAAI
Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial

主动脉瓣置换与保守治疗无症状重度主动脉瓣狭窄: AVATAR试验的长期随访

2024-09-012
OA
Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes-Results from a Multi-Center International Prospective Registry (HOPE-2)

新型冠状病毒肺炎住院和长期新型冠状病毒肺炎症状后的肌钙蛋白升高: 发病率,预后和临床结局-来自多中心国际前瞻性注册研究的结果 (HOPE-2)

2024-04-284
OAAI
Clinical Profile and Determinants of Mortality in Patients with Interstitial Lung Disease Admitted for COVID-19
2023-06-022
OAAI
Post-COVID-19 syndrome and diabetes mellitus: a propensity-matched analysis of the International HOPE-II COVID-19 Registry

Post-COVID-19综合征和糖尿病: 国际hope-ii新型冠状病毒肺炎登记的倾向匹配分析

2023-05-168
OAAI
Sacubitril/valsartan reverses cardiac structure and function in experimental model of hypertension-induced hypertrophic cardiomyopathy
2023-03-306
OA
Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)

Post-COVID-19症状和心脏病: 发病率,预后因素,结果和疫苗接种: 来自多中心国际前瞻性注册表 (HOPE 2) 的结果

2023-01-1611
OAAI